Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, DENTSPLY Sirona Inc (NASDAQ: XRAY) closed at $14.03 up 1.23% from its previous closing price of $13.86. In other words, the price has increased by $1.23 from its previous closing price. On the day, 2.71 million shares were traded. XRAY stock price reached its highest trading level at $14.31 during the session, while it also had its lowest trading level at $13.85.
Ratios:
For a deeper understanding of DENTSPLY Sirona Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.80 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.28. For the most recent quarter (mrq), Quick Ratio is recorded 1.11 and its Current Ratio is at 1.69. In the meantime, Its Debt-to-Equity ratio is 1.27 whereas as Long-Term Debt/Eq ratio is at 1.18.
On February 14, 2025, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $20.Wells Fargo initiated its Equal Weight rating on February 14, 2025, with a $20 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 03 ’25 when LUCIER GREGORY T bought 15,142 shares for $16.51 per share. The transaction valued at 249,994 led to the insider holds 81,971 shares of the business.
Coleman Glenn bought 15,759 shares of XRAY for $311,240 on Jan 27 ’25. On Nov 18 ’24, another insider, LUCIER GREGORY T, who serves as the Director of the company, bought 5,000 shares for $18.37 each. As a result, the insider paid 91,850 and bolstered with 71,730 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XRAY now has a Market Capitalization of 2798760448 and an Enterprise Value of 4915846144. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.76 while its Price-to-Book (P/B) ratio in mrq is 1.43. Its current Enterprise Value per Revenue stands at 1.339 whereas that against EBITDA is 7.853.
Stock Price History:
The Beta on a monthly basis for XRAY is 0.97, which has changed by -0.42944288 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, XRAY has reached a high of $27.48, while it has fallen to a 52-week low of $12.16. The 50-Day Moving Average of the stock is -8.79%, while the 200-Day Moving Average is calculated to be -16.54%.
Shares Statistics:
For the past three months, XRAY has traded an average of 3.00M shares per day and 4756410 over the past ten days. A total of 199.30M shares are outstanding, with a floating share count of 198.20M. Insiders hold about 0.64% of the company’s shares, while institutions hold 101.72% stake in the company. Shares short for XRAY as of 1753920000 were 7176058 with a Short Ratio of 2.39, compared to 1751241600 on 7888793. Therefore, it implies a Short% of Shares Outstanding of 7176058 and a Short% of Float of 4.01.
Dividends & Splits
According to the company, the forward annual dividend rate for XRAY is 0.64, from 0.64 in the trailing year. Against a Trailing Annual Dividend Yield of 0.046176046The stock’s 5-year Average Dividend Yield is 1.69.
Earnings Estimates
The stock of DENTSPLY Sirona Inc (XRAY) is currently in the spotlight, with 14.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $0.48, with high estimates of $0.55 and low estimates of $0.44.
Analysts are recommending an EPS of between $1.94 and $1.63 for the fiscal current year, implying an average EPS of $1.87. EPS for the following year is $2.03, with 15.0 analysts recommending between $2.3 and $1.93.
Revenue Estimates
A total of 14 analysts believe the company’s revenue will be $901.82M this quarter.It ranges from a high estimate of $915.8M to a low estimate of $889M. As of the current estimate, DENTSPLY Sirona Inc’s year-ago sales were $951MFor the next quarter, 14 analysts are estimating revenue of $939.69M. There is a high estimate of $975M for the next quarter, whereas the lowest estimate is $906M.
A total of 17 analysts have provided revenue estimates for XRAY’s current fiscal year. The highest revenue estimate was $3.68B, while the lowest revenue estimate was $3.62B, resulting in an average revenue estimate of $3.65B. In the same quarter a year ago, actual revenue was $3.79BBased on 16 analysts’ estimates, the company’s revenue will be $3.74B in the next fiscal year. The high estimate is $3.84B and the low estimate is $3.64B.
